Discover leading Sales & Marketing Intent Data Solutions for the Pharmaceutical ...
Amgen’s LUMAKRAS and Vectibix combination has received approval from the US FDA ...
The negotiated prices of 15 Medicare Part D drugs, which include several blockbu...
The metaverse hype is over, but developer Cassette Group has been working with P...
How longitudinal, closed claims data is advancing regulatory, epidemiology, and ...
Potential antitrust deregulation could foster a more favourable environment for ...
Charles River and Akron Bio have announced the integration of the latter’s CSS l...
The FDA has narrowly beaten the European Medicines Agency (EMA) to the most appr...
The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to so...
The Lonza CEO said the company is not under any pressure to exit the Capsules an...
Shionogi’s S-892216 is being developed as a pre-exposure prophylaxis (PrEP) drug...
IMPACT Therapeutics has received the China NMPA marketing authorisation for Sena...
AbbVie and Simcere Zaiming have announced an option-to-license agreement for the...
Incyte told JP Morgan attendees of plans for four launches in 2025, beginning wi...
Regenxbio will receive $110m upfront from Nippon Shinyaku and is eligible to get...
